Compare Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) vs Tidewater Inc — how do they compare? Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.68 (market cap $58.74B), while Tidewater Inc trades at $84.9 (market cap $4.21B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 14× Tidewater Inc's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while Tidewater Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days and Tidewater Inc for 26 Days on average.
| TAK | TDW | |
|---|---|---|
Market Cap | $58.74B | $4.21B |
Volume | 3,110,994 | 590,005 |
Sector | Health | Energy |
52-Week High | $19.05 | $100.61 |
52-Week Low | $13.23 | $47.29 |
Typical Hold Time | 1 Days | 26 Days |
Enterprise Value | $86.65B | $4.25B |
Dividend Yield | 3.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Tidewater (TDW) trades at $85.42, up 2.42% with bullish technical indicators and strong institutional interest. The company maintains solid profitability with 18.34% net margin and 19.49% ROE, though recent quarterly earnings have missed expectations. Recent acquisition of Wilson Sons Ultratug expands offshore services capabilities, while BlackRock's $503 million investment signals confidence in long-term prospects.
TDW presents a mixed outlook with analyst consensus target of $105.50 offering 23% upside potential, but faces execution risks from recent earnings misses and Middle East operational costs. The stock's valuation at 17.18 P/E appears reasonable given growth prospects, though investors should monitor quarterly performance consistency and integration of recent acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
